682805-12-5 Usage
General Description
2-Chloro-5-(trifluoromethyl)cinnamic acid is a chemical compound with a specific molecular formula of C10H6ClF3O2. This formula signifies that it is composed of 10 carbon (C) atoms, 6 hydrogen (H) atoms, a single chlorine (Cl) atom, 3 fluorine (F) atoms and 2 oxygen (O) atoms. 2-CHLORO-5-(TRIFLUOROMETHYL)CINNAMIC ACID usually appears as a solid and is often used in laboratory research settings or in industrial applications. It is a derivative of cinnamic acid, with the additional content of chlorine and trifluoromethyl groups. The trifluoromethyl group, specifically, makes the compound more stable and resistant to harsh or strong conditions, such as high temperatures or strong acid or base solutions, by increasing its density and boiling points. Due to the chlorine and trifluoromethyl substitutions, this chemical exhibits different properties as compared to its parent cinnamic acid compound.
Check Digit Verification of cas no
The CAS Registry Mumber 682805-12-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,8,2,8,0 and 5 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 682805-12:
(8*6)+(7*8)+(6*2)+(5*8)+(4*0)+(3*5)+(2*1)+(1*2)=175
175 % 10 = 5
So 682805-12-5 is a valid CAS Registry Number.
682805-12-5Relevant articles and documents
Design, synthesis and cytotoxic evaluation of novel imatinib amide derivatives that target Abl kinase
Yao, Ri-Sheng,Guan, Qiu-Xiang,Lu, Xiao-Qin,Ruan, Ban-Feng
, p. 20 - 28 (2015/03/31)
Novel imatinib amide derivatives (a1-28, b1-9) were synthesized and evaluated for their biological activities. All compounds were characterized by 1H NMR, MS and elemental analysis. Among all the derivatives, compounds a4, a10, a21, b1 and b2 displayed the most significant ability of inhibiting K562 cell proliferation with the IC50 values of 0.67, 0.66, 0.65, 0.59 and 0.62 μM, respectively, indicating that these compounds were potent inhibitors of Bcr-Abl in leukemic K562 cells, comparable to the reference compound imatinib. Molecular docking study was performed to position compounds a21 and b1 into the active site of Abl to determine the probable binding modes
